Trending...
- California: Governor Newsom announces completion of major Sacramento Valley flood project ahead of El Niño - 108
- California: Governor Newsom, Acting Governor Limón lower flags as Dolores Huerta is laid to rest - 102
- Flat 6 Concepts Releases 2027 Creative Pricing Guide, Showing What Businesses Really Pay for Branding, Websites, Content, Social Media and PR
JUPITER, Fla. - Californer -- First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr. Jeff Gelblum are among the first physicians in the country to administer the newly FDA-approved drug Kisunla to patients. This groundbreaking development marks a significant milestone in neurological care, offering new hope to patients battling a range of neurological conditions.
Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.
More on The Californer
He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."
Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."
Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent. We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."
More on The Californer
The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.
About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.
For more information about Kisunla and First Choice Neurology, visit fcneurology.com
Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.
More on The Californer
- Ella Langley Hits the 2026 CMA Awards Red Carpet in Custom KmXtend Clip-In Extensions Styled by Chris Bear
- Teens Wanna Know Launches Friday, Unread Interactive Vertical Thriller Microdrama
- California: Governor Newsom announces appointments
- Say Hello to Rising New wave artist TJ Jones
- West Coast Aluminum & Stainless Now Offering Aluminum Extrusions
He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."
Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."
Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent. We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."
More on The Californer
- California: Governor Newsom proclaims Transgender Day of Remembrance
- Feast Safely: City of Long Beach Offers Tips for a Safe Thanksgiving
- Purple Camero Releases New Single "Mary Lies"
- SEEAG Launches First Harvest Fundraising Campaign for Southbank Learning Farm
- KeysCaribbean Introduces Newly Reduced Rates At Village at Hawks Cay Villas for Thanksgiving Getaways
The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.
About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.
For more information about Kisunla and First Choice Neurology, visit fcneurology.com
Source: First Choice Neurology
Filed Under: Health
0 Comments
Latest on The Californer
- Own a Lodge at Joshua Tree National Park
- 17th Annual Zed Fest Film Festival 2026 Runs Nov 18-22, 2026 AMC/LA Connection Theatre Burbank
- Matt Zavala of Zavala Law, PC Elected to Ventura County Bar Association Board of Directors
- CapitalMarketsAI Publishes Product Demonstration of Its SEC Filing Intelligence Platform
- Montana Artist Ryan Jolley Receives Goodman Award at Mountain Oyster Club Art Show
- Old Ink Records Grounds Its Operations in Solarpunk, Becoming an Engine for the Movement
- Make Your Move to Luxury Living at Heritage at Hopewell with Rates Starting at Just 3.750% (5.803% APR)
- San Diego Premiere of "Mrs. Christmas," a Holiday Musical by Award-Winning Playwright Tom Jacob
- City of Long Beach Issues Rain Advisory Due to Recent Showers
- Cards Cash Rewards Launches Featured Products Initiative
- Scott Glickson Joins STS Capital Partners as Managing Director
- BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
- California: Claim your cash: Millions in CalKIDS scholarships available for community college students
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth
- Black Friday Jewellery Deals 2026: Best Affordable Luxury Bracelets & Gifts for Her
- First Partner Siebel Newsom hosts California Love, California Strong community event celebrating California agriculture and farming communities
- PinnacleQM launches new enterprise website to help Australian organisations deliver more with confidence
- San Diego's MTG Wholesale Expands Direct Wholesale Mortgage Access Across California
- California: Governor Newsom addresses crisis facing boys and men at national summit in Washington, DC
- Long Beach: United States Loses Measles Elimination Status
